ImmunoGen, Inc. (IMGN): Price and Financial Metrics


ImmunoGen, Inc. (IMGN): $5.68

-0.26 (-4.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

IMGN POWR Grades


  • IMGN scores best on the Value dimension, with a Value rank ahead of 75.08% of US stocks.
  • IMGN's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • IMGN's current lowest rank is in the Momentum metric (where it is better than 9.5% of US stocks).

IMGN Stock Summary

  • Of note is the ratio of ImmunoGen Inc's sales and general administrative expense to its total operating expenses; merely 10.77% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for ImmunoGen Inc is higher than it is for about just 14.87% of US stocks.
  • As for revenue growth, note that IMGN's revenue has grown 58.05% over the past 12 months; that beats the revenue growth of 88.95% of US companies in our set.
  • Stocks that are quantitatively similar to IMGN, based on their financial statements, market capitalization, and price volatility, are WVE, MGNX, ABUS, PTGX, and IDYA.
  • Visit IMGN's SEC page to see the company's official filings. To visit the company's web site, go to www.immunogen.com.

IMGN Valuation Summary

  • In comparison to the median Healthcare stock, IMGN's price/earnings ratio is 160% lower, now standing at -21.9.
  • IMGN's price/earnings ratio has moved up 60.5 over the prior 243 months.
  • IMGN's EV/EBIT ratio has moved up 60 over the prior 243 months.

Below are key valuation metrics over time for IMGN.

Stock Date P/S P/B P/E EV/EBIT
IMGN 2021-08-31 8.9 17.8 -21.9 -18.0
IMGN 2021-08-30 8.7 17.4 -21.4 -17.5
IMGN 2021-08-27 9.0 17.9 -22.0 -18.1
IMGN 2021-08-26 8.5 17.0 -20.8 -16.9
IMGN 2021-08-25 8.3 16.6 -20.4 -16.5
IMGN 2021-08-24 8.2 16.3 -20.1 -16.2

IMGN Growth Metrics

  • Its year over year price growth rate is now at 58.01%.
  • The 3 year net income to common stockholders growth rate now stands at -34.48%.
  • The 3 year net cashflow from operations growth rate now stands at 11.46%.
Over the past 33 months, IMGN's revenue has gone up $57,163,000.

The table below shows IMGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 136.641 -110.612 -55.778
2021-03-31 134.718 -94.926 -49.335
2020-12-31 132.299 -78.62 -44.372
2020-09-30 91.365 -119.712 -70.946
2020-06-30 86.457 -124.065 -70.322
2020-03-31 86.974 -126.885 -89.47

IMGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IMGN has a Quality Grade of C, ranking ahead of 31.09% of graded US stocks.
  • IMGN's asset turnover comes in at 0.437 -- ranking 105th of 677 Pharmaceutical Products stocks.
  • RMTI, PTE, and GILD are the stocks whose asset turnover ratios are most correlated with IMGN.

The table below shows IMGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.437 1 1.612
2021-03-31 0.442 1 1.694
2020-12-31 0.452 1 2.339
2020-09-30 0.347 1 9.437
2020-06-30 0.327 1 10.967
2020-03-31 0.323 1 39.802

IMGN Price Target

For more insight on analysts targets of IMGN, see our IMGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.79 Average Broker Recommendation 1.55 (Moderate Buy)

IMGN Stock Price Chart Interactive Chart >

Price chart for IMGN

IMGN Price/Volume Stats

Current price $5.68 52-week high $10.88
Prev. close $5.94 52-week low $3.46
Day low $5.66 Volume 866,600
Day high $5.91 Avg. volume 1,952,192
50-day MA $5.70 Dividend yield N/A
200-day MA $6.97 Market Cap 1.15B

ImmunoGen, Inc. (IMGN) Company Bio


Immunogen develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The company was founded in 1981 and is based in Waltham, Massachusetts.


IMGN Latest News Stream


Event/Time News Detail
Loading, please wait...

IMGN Latest Social Stream


Loading social stream, please wait...

View Full IMGN Social Stream

Latest IMGN News From Around the Web

Below are the latest news stories about ImmunoGen Inc that investors may wish to consider to help them evaluate IMGN as an investment opportunity.

Leerink Partners Stick to Their Hold Rating for Immunogen By Investing.com

Leerink Partners Stick to Their Hold Rating for Immunogen

Investing.com | August 6, 2021

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., August 02, 2021--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo | August 2, 2021

ImmunoGen (IMGN) Q2 Loss Narrower Than Expected, Revenues Lag

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates.

Yahoo | August 2, 2021

ImmunoGen, inc (IMGN) Q2 2021 Earnings Call Transcript

At this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications and Investor Relations. With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Susan Altschuller, our CFO.

Yahoo | July 30, 2021

ImmunoGen (IMGN) Reports Q2 Loss, Misses Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 16.67% and -10.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 30, 2021

Read More 'IMGN' Stories Here

IMGN Price Returns

1-mo -6.73%
3-mo -13.81%
6-mo -30.82%
1-year 58.66%
3-year -40.02%
5-year 114.34%
YTD -11.94%
2020 26.35%
2019 6.35%
2018 -25.12%
2017 214.22%
2016 -84.97%

Continue Researching IMGN

Want to see what other sources are saying about ImmunoGen Inc's financials and stock price? Try the links below:

ImmunoGen Inc (IMGN) Stock Price | Nasdaq
ImmunoGen Inc (IMGN) Stock Quote, History and News - Yahoo Finance
ImmunoGen Inc (IMGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.1391 seconds.